title: Reversible slurred speech related to capecitabine and lapatinib combination in patients with breast cancer.
abstract: Capecitabine plus lapatinib combination is an effective chemotherapy regimen in patients with advanced breast cancer. Neurological adverse effects secondary to this regimen were reported rarely in literature. A woman with breast cancer presented with complaints of slurred speech while using the capecitabine and lapatinib combination. Her major complaint was slurred speech. No other radiologic or laboratory disorders were detected in the patient. Slurred speech improved one week after the capecitabine and lapatinib combination was discontinued without any further intervention.
authors.affiliation: Department of Medical Oncology, Acibadem Kayseri Hospital, Kayseri, Turkey doktorhasanmutlu@gmail.com.
authors.forename: Hasan
authors.initials: H
authors.lastname: Mutlu
authors.affiliation: Department of Internal Medicine, Acibadem University School of Medicine, Istanbul, Turkey.
authors.forename: Abdullah
authors.initials: A
authors.lastname: Büyükçelik
authors.affiliation: Department of Radiation Oncology, Mersin Goverment Hospital, Mersin, Turkey.
authors.forename: Zeki
authors.initials: Z
authors.lastname: Akça
authors.affiliation: Department of Internal Medicine, Kayseri Training and Research Hospital, Kayseri, Turkey.
authors.forename: Abdülsamet
authors.initials: A
authors.lastname: Erden
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001184:Articulation Disorders / Q000139:chemically induced*; D001943:Breast Neoplasms / Q000188:drug therapy*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D000077341:Lapatinib; D008875:Middle Aged; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000077341:Lapatinib; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil
keywords: Capecitabine; adverse event; breast cancer; lapatinib; speech